PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 16, 2021Journal of Thoracic OncologyOpen Access

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

DCD. Ross CamidgeHKHye Ryun KimMAMyung‐Ju Ahn

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Camidge et al. (2021) studied this question.

synapsesocial.com/papers/690928dce2a3c54d85885d37https://doi.org/10.1016/j.jtho.2021.07.035
View Full Paper
Ask AI
Bookmark
Share